The command center announced that two new types of pre-exposure monoclonal antibodies will be applicable, including blood cancer patients and HIV-infected patients with valid major injury and disease cards.

(Picture provided by Command Center)

[Reporter Wu Liangyi/Taipei Report] In response to the local epidemic of Wuhan pneumonia (new coronavirus disease, COVID-19), the Central Epidemic Command Center announced today that two new types of pre-exposure prophylactic monoclonal antibodies for Wuhan pneumonia are applicable, including those with effective Hematological cancer patients with serious injury cards and HIV-infected patients.

my country purchased 10,000 doses of monoclonal antibodies, and about 1,200 doses have been used.

The Epidemic Command Center announced today that in order to maximize the effectiveness of the use of Wuhan pneumonia drugs and reduce the risk of severe illness and death, according to the recommendations of the US Food and Drug Administration and the National Institutes of Health, two new types of pre-exposure prophylactic monoclonal antibody Evusheld are applicable.

Please read on...

The command center stated that after the addition of these two types of subjects, my country's current preventive monoclonal antibody targets include the highest-risk groups recommended by the US Food and Drug Administration and the National Institutes of Health.

☆Health news will never be missed, click like to follow the fan page.


☆For more important medical news, please go to Liberty Health.com.

keywords

  • high risk groups

  • HIV carrier

  • Wuhan Pneumonia (Novel Coronavirus Disease, COVID-19)

  • monoclonal antibody

related news